Clinical Trials Logo

Filter by:
NCT ID: NCT02721966 Completed - Clinical trials for Axial Psoratic Arthritis

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

MAXIMISE
Start date: October 3, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).

NCT ID: NCT02721641 Completed - Cancer Clinical Trials

A Continuation Study of Trastuzumab (Herceptin) in Participants With Metastatic or Locally Advanced Cancer

Start date: June 1999
Phase: Phase 3
Study type: Interventional

This study evaluated the long-term safety of treatment with trastuzumab in participants with metastatic or locally advanced cancer with human epidermal growth factor 2 (HER2) overexpression who had completed a prior study with trastuzumab.

NCT ID: NCT02721498 Completed - Cystic Fibrosis Clinical Trials

Improving Outcome Measures For Adult CF ACT Trials

Start date: September 2016
Phase: N/A
Study type: Interventional

This is a randomised controlled cross-over trial involving adult cystic fibrosis (CF) patients from the Royal Brompton Hospital, London investigating outcome measures used in airway clearance trials. Each participant will attend the research facility for two visits. Participants will be randomly assigned to the order that they perform the study sessions. Visit A will involve a period of rest for up to 60 minutes in-between assessments; Visit B will involve a session of airway clearance (ACT) utilising ACBT supervised by a specialist physiotherapist in adult CF. Participants will perform the outcome measure (OM) tests of impulse oscillation system (IOS), lung clearance index (LCI), and spirometry, then either rest (visit A) or perform a supervised ACBT session (visit B) using electronic impedance tomography (EIT) during the session. IOS, LCI and spirometry will be repeated after the session. Sputum will be collected throughout the ACT or rest sessions and for 30 minutes after each of these sessions is completed. Questionnaires asking patient views on the OMs will be completed at the end of each study visit. Analysis will be based upon differences in outcome measures and in-between study days.

NCT ID: NCT02721199 Completed - COPD Clinical Trials

EMG in COPD - Factor Analysis

EMGCOPD
Start date: January 2016
Phase: N/A
Study type: Observational

Acute exacerbations of COPD contribute to significant morbidity and mortality in the United Kingdom (UK). The ability to assess response to treatment during exacerbations that require hospitalisation would allow clinicians to better risk stratify patients for higher or lower level in-patient or out-patient care. Current methods of detecting clinical deterioration are validated in general medical populations and may lack sensitivity and specificity in patients with respiratory morbidity. The use of respiratory muscle EMG to assess neural respiratory drive (NRD) has been demonstrated to be a predictor of readmission in patients admitted to hospital with COPD. The technique has been applied on 'spot' readings of limited duration due to the need for hand analysis of the data. It has been performed by a trained clinical physiologist who removed any interference data and standardised the data gathered. New automated software allows for longer periods of observation, mostly unsupervised, and as a result, the NRD measurements are more likely to be affected by various sources of variability. The influence of clinical and physiological factors as they occur during routine clinical management, such as administration of bronchodilator medication, time of day of readings or proximity to chest physiotherapy, are not yet understood. This trial is designed to gather data to better understand these relationships with NRD.

NCT ID: NCT02721108 Completed - Chronic Pelvic Pain Clinical Trials

Mindfulness Meditation for Chronic Pelvic Pain Management

MEMPHIS
Start date: May 2016
Phase: N/A
Study type: Interventional

Chronic pelvic pain (CPP) in women is common, painful and disabling and puts much strain on women's lives and the (National Health Service) NHS. CPP may be related to internal organs, the nervous system or psychological factors and is often difficult to treat. Surgery and drugs have risks and side effects, are expensive and do not help all patients. Psychological treatments have potential to improve CPP but are not consistently available. Mindfulness meditation teaches people to accept their sensations and emotions in the present moment. This can help to accept pain better, which enables patients to focus on daily activities and improve their quality of life. It has been shown to help in headache, back pain and depression. Usually mindfulness meditation is taught by attending courses for 8 weeks. The investigators want to find out in a full-scale trial if mindfulness meditation, taught by using a smartphone app, can help CPP patients. In preparation for this full-scale study the investigators will conduct the MEMPHIS study to answer the following questions: - How many patients are willing to participate? - How often they use the app? - Reasons for not wanting to participate/not using the app - - Which health questionnaires are the most useful ones? - How many patients will be required for the full-scale trial? Patients will receive the usual treatment and be divided into three groups - using a 60-day mindfulness meditation app, -- using comparison app with progressive muscle relaxation but no meditation - no app Patients will complete health questionnaires, may be asked to comment in a focus group and record pain, medication changes, surgery and emergency medical visits

NCT ID: NCT02720900 Completed - Autism Clinical Trials

Prebiotic Intervention for Autism Spectrum Disorders

Start date: September 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of a prebiotic (BGOS) on gut microbiota and metabolites in children with autism spectrum disorders.

NCT ID: NCT02720640 Completed - Clinical trials for Retinitis Pigmentosa

Safety and Efficacy of the Alpha AMS Subretinal Implant

OX-RI
Start date: May 2015
Phase: N/A
Study type: Interventional

The aim of this single-centre study is to assess the safety and efficacy of the Retina Implant Alpha AMS (Retina Implant AG, Reutlingen, Germany) in participants with severe visual impairment secondary to outer retinal degeneration caused by retinitis pigmentosa (RP). The study is sponsored by the University of Oxford and funded by the National Institute for Health Research (UK).

NCT ID: NCT02720224 Completed - Contraception Clinical Trials

Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

Start date: February 2016
Phase: Phase 1
Study type: Interventional

This study is being conducted to further understand the elimination pathways, metabolite profile and pharmacokinetic (PK) profile of carbon 14 labelled estetrol ([14C] estetrol).

NCT ID: NCT02720055 Completed - Fractures, Bone Clinical Trials

Rehabilitation Workbook After Wrist Fracture.

Start date: March 2016
Phase: N/A
Study type: Interventional

A randomised controlled trial to compare two different rehabilitation work books used in patients with wrist fracture.

NCT ID: NCT02720042 Completed - Hernia Clinical Trials

Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Start date: March 23, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to collect additional data on safety and performance of Phasix™ Mesh in subjects requiring Ventral Hernia Working Group (VHWG) Grade 3 midline hernia repair.